Has bovine somatotropin (BST) an effect upon drug disposition? Comparative studies in goats and cattle with sulphadimidine and antipyrine after parenteral administration of BST, zeranol and proligestone (original) (raw)
Related papers
Journal of dairy science, 1991
Postparturient metabolic and production responses were studied for 85 multiparous cows consisting of controls and animals that had been previously exposed to long-term treatment with bST. Older cows previously exposed to bST at high doses (51.6 mg/d) had lower milk yields than controls. However, there were no significant differences compared with controls in milk yield for lower dose (17.2 mg/d) older cows or parity 2 cow groups. The bST-treated groups had higher postpartum DMI, lower serum FFA, lower serum beta-hydroxybutyrate levels, and higher serum glucose than controls. Some bST-exposed groups had lower milk fat but higher milk protein levels. All bST-treated groups had significantly lower ratios of C18 to C4 to 10 milk fatty acids. Control cows of both parity groups were in higher body condition and weighed more than bST-treated cows prior to calving. The differences in postpartum metabolism may be attributed to differences in body composition resulting from bST treatment in t...
2000
This manuscript presents the results of a review of the effects of recombinant bovine somatotropin (rBST) on dairy cattle health, reproductive performance, and culling, that was carried out by an expert panel established by the Canadian Veterinary Medical Association (CVMA). The panel was established by the CVMA in response to a request from Health Canada in 1998 and their report was made public in 1999. A series of meta-analyses was used to combine data on health-related parameters that were extracted from all randomized clinical trials that had been published in peer-reviewed journals or which were provided by Health Canada from the submission by Monsanto for registration of rBST in Canada. A companion paper (1) presents the estimates of the effect of the drug on production parameters. Recombinant bovine somatotropin was found to increase the risk of clinical mastitis by approximately 25% during the treatment period but there was insufficient data to draw firm conclusions about the effects of the drug on the prevalence of subclinical intra-mammary infections. Use of rBST increased the risk of a cow failing to conceive by approximately 40%. For cows which did conceive, there was no effect on services per conception and only a small increase in average days open (5 days). Use of the drug had no effect on gestation length, but the information about a possible effect on the risk of twinning was equivocal. Cows treated with rBST had an estimated 55% increase in the risk of developing clinical signs of lameness. Few studies reported data on culling, but based on those that did, there appeared to be an increase risk of culling evident in multiparous cows. Use of the drug in 1 lactation period appeared to reduce the risk of metabolic diseases (particularly ketosis) in the early period of the subsequent lactation.
Bovine somatotropin: review of an emerging animal technology
Journal of dairy science, 1992
One of the first potential biotechnology products for animal production is bST. Research in the technology of bST has involved scientists and support from federal agencies, universities, and private industry. As a consequence of this extensive cooperation, more than 1000 bST studies have been conducted, which involved over 20,000 dairy cows, and results have been confirmed by scientists throughout the world. This quantity of published research is unprecedented for a new technology and greater than most dairy technologies in use. In contrast to steroids, bST is a protein hormone. Milk yield and persistency responses to bST have been observed for all dairy breeds examined. Quality of management is the major factor affecting magnitude of milk response to bST. The mechanism of action of bST involves a series of orchestrated changes in the metabolism of body tissues so that more nutrients can be used for milk synthesis. It is these coordinated changes that allow the animal to achieve an ...
Journal of Dairy Science, 1989
Eighty Holstein cows (first, second, or third lactation) were used to evaluate the efficacy of a prolonged-release formulation for sometribove (n-methionyl bovine somatotropin). Cows were fed ad libitum a complete mixed diet and milked twice daily. Cows were allocated randomly by parity to two treatment groups receiving 500 mg sometribove in a prolonged release formulation or excipient at 14-d intervals starting at 60 + 3 d postpartum and continuing for 36 wk. Treatment with sometribove increased FCM yield to a similar extent (11.4%, +3.1 kg/d) in primiparous and multiparous animals. Milk content of lactose, fat, ash, and Ca was not affected, but protein and phosphorous were slightly greater (<5%) in milk from sometribove-treated cows. Within a 14-d injection interval, animals treated with sometribove displayed a cyclic pattern in milk yield, but a similar pattern was not evident in feed intake.